- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4196 - 1,2,4-Triazoles
Patent holdings for IPC class A61K 31/4196
Total number of patents in this class: 2902
10-year publication summary
|
218
|
184
|
227
|
254
|
237
|
211
|
185
|
176
|
188
|
96
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Synta Pharmaceuticals Corp. | 179 |
77 |
| Axsome Therapeutics, Inc. | 245 |
57 |
| F. Hoffmann-La Roche AG | 7926 |
49 |
| Novartis AG | 10904 |
48 |
| Karyopharm Therapeutics Inc. | 142 |
38 |
| Genentech, Inc. | 3961 |
31 |
| Merck Sharp & Dohme LLC | 3741 |
31 |
| Hoffmann-La Roche Inc. | 3379 |
30 |
| Bayer Pharma AG | 1061 |
30 |
| Boehringer Ingelheim International GmbH | 4704 |
28 |
| Ardea Biosciences, Inc. | 73 |
28 |
| Gilead Sciences, Inc. | 2028 |
27 |
| Bristol-myers Squibb Company | 4892 |
24 |
| Pfizer Inc. | 3367 |
23 |
| The Regents of the University of California | 19812 |
20 |
| Havah Therapeutics Pty Ltd | 20 |
19 |
| BASF SE | 20777 |
18 |
| Eli Lilly and Company | 3814 |
18 |
| Rigel Pharmaceuticals, Inc. | 540 |
18 |
| Theravance Biopharma R&D IP, LLC | 462 |
18 |
| Other owners | 2270 |